For anyone invested in the future of peptide therapy, the dates July 23 and 24, 2026, have been circled on the calendar for months. Over those two days, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will convene at the agency’s White Oak campus in Maryland to review seven of the most discussed peptides in the wellness and longevity space.
If you have spent any time in peptide communities recently, you have likely heard this described as a high-stakes battle over whether these substances will be moved to "Category 1" or banished to "Category 2." It is easy to see why that shorthand caught on. For years, those categories dictated whether a compounding pharmacy could legally prepare a prescription for you.
However, the regulatory landscape has shifted, and the actual question before the committee is both simpler and more profound. The FDA is no longer sorting new nominations into interim categories. Instead, the agency is asking its advisory committee whether these seven peptides—BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax—should be formally included on the 503A Bulks List 1.
If a substance makes the final list, state-licensed pharmacies can use it to compound patient-specific medications. If it does not, access through legitimate U.S. pharmacies will likely contract sharply.
As we approach this pivotal meeting, it is crucial to understand the two-day agenda, what the FDA staff has already concluded, and what the realistic odds are for the peptides on the docket.
Breaking Down the Two-Day Agenda
The PCAC meeting is structured to evaluate the seven peptides sequentially. The committee will hear presentations from FDA reviewers, take public comment, discuss the evidence, and vote on whether to recommend each substance for the 503A Bulks List. The updated agenda lists Day 1 from 8:00 a.m. to 6:20 p.m. ET and Day 2 from 8:00 a.m. to 4:15 p.m. ET 3.
| Day and approximate session start | Peptide on the docket | Uses FDA will evaluate |
|---|---|---|
| Thursday, July 23 — 8:55 a.m. | BPC-157 | Ulcerative colitis |
| Thursday, July 23 — 12:15 p.m. | KPV | Wound healing and inflammatory conditions |
| Thursday, July 23 — 2:55 p.m. | TB-500 | Wound healing |
| Thursday, July 23 — 4:40 p.m. | MOTS-c | Obesity and osteoporosis |
| Friday, July 24 — 8:55 a.m. | Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, and narcolepsy |
| Friday, July 24 — 11:15 a.m. | Semax | Cerebral ischemia, migraine, and trigeminal neuralgia |
| Friday, July 24 — 2:10 p.m. | Epitalon | Insomnia |
Day 1 therefore centers on gastrointestinal inflammation, wound repair, and metabolic disease. Day 2 shifts toward sleep, neurological conditions, pain, and opioid withdrawal. For every peptide, the FDA is evaluating both the free base and acetate forms—not merely the familiar shorthand name used in clinics and online communities 3.
The End of Categories: What the Vote Actually Means
To understand the stakes, we have to clarify the terminology. "Category 1" and "Category 2" are legacy terms from an interim FDA policy.
Historically, Category 1 meant a substance was nominated with sufficient supporting information, and the FDA generally exercised enforcement discretion—meaning they would not take action against a pharmacy for compounding it while it was under review. Category 2 meant the FDA had identified significant safety risks and would not offer that same enforcement discretion, making the substance much harder to obtain legally 4.
All seven of the peptides on this month's docket were, at one point, placed in the Category 2 safety-risk group before their nominations were withdrawn 5. However, effective January 2025, the FDA finalized a policy ending the use of these interim categories for new nominations 2.
The July PCAC meeting is not a vote to move a peptide from Category 2 to Category 1. It is a vote on whether the committee agrees with the FDA's formal proposal regarding the 503A Bulks List.
If a peptide is eventually placed on the 503A Bulks List, it establishes a lawful federal pathway for traditional pharmacies to compound it for individual patients. It is important to note that this is not the same as FDA approval of a finished drug, but it provides regulatory clarity and secures patient access through licensed, domestic compounding facilities.
If a peptide is excluded from the list—and it has no applicable USP/NF drug-substance monograph and is not a component of an FDA-approved drug—compounding it generally prevents the resulting product from qualifying for crucial Section 503A exemptions. This does not make the substance illegal to possess, and the advisory vote itself does not cause an overnight change. But a final negative FDA decision would leave traditional U.S. pharmacies without a clear federal compounding pathway and may push more demand toward unregulated overseas research-chemical suppliers.
The FDA Staff Position: A Steep Uphill Climb
If you read the briefing documents the FDA prepared for the committee, the agency’s stance is unambiguous: FDA staff is proposing that every free-base and acetate form of all seven peptides NOT be included on the 503A Bulks List 6.
The FDA applies a four-factor balancing test: physical and chemical characterization, safety issues, evidence of effectiveness, and historical use in compounding. Across the board, reviewers found the data lacking 6.
For KPV, TB-500, and MOTS-c, the FDA stated it could not find any human clinical studies evaluating their effectiveness for the proposed uses 7 9. For BPC-157, Semax, and emideltide, the agency characterized the available human trials as small, poorly controlled, or inconclusive 10 12.
Safety and manufacturing concerns were also a recurring theme. Because these peptides are primarily intended for injection or nasal administration, the FDA repeatedly flagged the potential for immunogenicity—the risk that the body might mount an immune response to the peptide or to impurities generated during manufacturing 6. The agency also noted that for almost all the proposed indications, there are already FDA-approved therapies available.
Assessing the Odds: Consensus and Probabilities
With the FDA staff firmly opposed to inclusion, what are the realistic chances that the advisory committee will vote in favor of these peptides?
It is a complex calculation. The PCAC is an advisory body; its votes are non-binding, though the FDA generally follows its recommendations. The committee’s composition has recently changed, and several new members have ties to the peptide industry or integrative medicine clinics 13. Furthermore, Health and Human Services Secretary Robert F. Kennedy Jr. has been a vocal proponent of peptides, creating a unique dynamic between career scientists and agency leadership 13.
Because there is no formal expert consensus, any probability estimates are inherently subjective. However, we can look at how different voices in the space are evaluating the landscape.
In a recent interview, Dr. Jesse Morse, a sports medicine physician and vocal peptide advocate, offered his personal estimates for a favorable outcome: BPC-157 (75–80%), KPV (70–80%), MOTS-c (70–80%), Epitalon (~75%), Semax (~60%), TB-500 (50/50), and emideltide (≤50%) 14. These numbers reflect strong optimism within the prescribing community, driven by clinical experience and frustration with the current restrictions.
However, an evidence-weighted editorial assessment—balancing the enthusiasm of practitioners against the rigorous, often rigid standards of the FDA’s formal review process—suggests a more cautious outlook for the committee's recommendation.
| Peptide | Advocate Estimate (Dr. Morse) | Evidence-Weighted Estimate | Rationale for Evidence-Weighted Estimate |
|---|---|---|---|
| BPC-157 | 75–80% | 45% | It has the highest public interest and some limited human evidence, but the mismatch between proposed routes and available data, combined with the FDA’s detailed characterization and safety objections, remains a substantial hurdle. |
| Emideltide (DSIP) | ≤50% | 40% | It possesses the deepest human research history of the seven, which may carry weight with the committee, but the trials are small, inconsistent, and often use routes other than the proposed subcutaneous injection. |
| Semax | ~60% | 35% | Its history of human use and overseas registration creates a fuller record than several peers. However, the FDA cited weak trial designs and raised specific concerns about bleeding risks, abuse potential, and formulation issues. |
| KPV | 70–80% | 30% | As a short, biologically plausible peptide, topical uses may be perceived as lower risk. Yet, the FDA's finding of zero human exposure or efficacy data makes a positive recommendation difficult to justify under the agency's framework. |
| MOTS-c | 70–80% | 30% | There is massive enthusiasm around its metabolic potential, but the complete lack of human exposure data for the nominated substance and broad uncertainty about targets and dosing are significant liabilities. |
| Epitalon | ~75% | 30% | It has some overseas literature and a straightforward rationale for sleep, but this is offset by the lack of adequate insomnia evidence for the proposed route and unresolved questions regarding telomerase activation and carcinogenicity. |
| TB-500 | 50% | 25% | The FDA found no human clinical evidence for the docketed wound-healing use, alongside impurity questions and weak in-vitro support for the intact peptide. |
Looking Ahead
Whatever happens on July 23 and 24, the story will not end there. A positive vote from the PCAC would be a monumental victory for patient access, signaling that the committee believes the clinical benefits and the safety of regulated compounding outweigh the gaps in the formal literature. But it would still only be a recommendation, subject to final FDA rulemaking.
A negative vote would validate the FDA staff’s stringent evidentiary standards but would undoubtedly frustrate thousands of patients and practitioners who rely on these therapies. It would also amplify the ongoing debate about the gray market, because restricting access through licensed pharmacies may drive some consumers toward less regulated sources 15.
The peptide landscape is evolving rapidly. We are moving away from the era of regulatory ambiguity and toward a framework where these substances must stand up to formal scrutiny. The upcoming PCAC meeting is the most significant test of that new reality yet. We will be watching closely.
This article is for educational purposes and does not provide medical advice. Peptides discussed here are not FDA-approved for the uses reviewed at this meeting.